Literature DB >> 29239815

Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey.

Terry A Jacobson1, Abdullah Khan2, Kevin C Maki3, Eliot A Brinton4, Jerome D Cohen5.   

Abstract

BACKGROUND: Statin-associated muscle symptoms are reported by 10% to 29% of patients in clinical practice and are a major determinant of statin nonadherence, discontinuation, and switching. Little is known about what advice patients receive from their providers when dealing with these symptoms.
OBJECTIVE: The objective of the study was to assess patient's reports of provider advice when experiencing new or worsened muscle symptoms while taking a statin.
METHODS: Data were analyzed from the Understanding Statin Use in America and Gaps in Education survey, a self-administered internet-based survey of 10,138 adults with a reported history of high cholesterol and statin use.
RESULTS: Of the respondents, 60% of former statin users (n = 1220) reported ever experiencing new or worsened muscle pain on a statin, in contrast to 25% of current users (n = 8918; P < .001). Former statin users reported stopping more statins because of muscle symptoms (mean ± standard deviation, 2.2 ± 1.7) compared with current users (mean 1.6 ± 1.5, P < .0001). For those with muscle-related symptoms while on a statin, participants reported that providers most often suggested switching to another statin (33.8%), stopping the statin (15.9%), continuing the statin with further monitoring of muscle symptoms (12.2%), reducing the statin dose (9.8%), or getting a blood test for signs of muscle damage (9.2%). A lower percentage were advised to add either vitamin D (7.0%) or coenzyme Q10 (5.8%), or to switch to nonstatin therapy (6.1%) or red yeast rice (2.6%).
CONCLUSIONS: This study highlights patient experience with statin-associated muscle symptoms and the strategies recommended by providers in managing these symptoms. More research is needed to develop patient-centric and evidence-based approaches to managing statin-associated muscle symptoms, which is especially important in light of recent data showing increased cardiovascular risk among those who discontinue statin therapy.
Copyright © 2017 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HMG-CoA reductase inhibitors (statins); Muscle pain; Muscle weakness; Myalgia; Statin intolerance

Mesh:

Substances:

Year:  2017        PMID: 29239815     DOI: 10.1016/j.jacl.2017.09.006

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  3 in total

1.  The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care.

Authors:  Jason L Vassy; Charles A Brunette; Nilla Majahalme; Sanjay Advani; Lauren MacMullen; Cynthia Hau; Andrew J Zimolzak; Stephen J Miller
Journal:  Contemp Clin Trials       Date:  2018-10-24       Impact factor: 2.226

2.  Understanding Patient Adherence and Concerns with STatins and MedicatION Discussions With Physicians (ACTION): A survey on the patient perspective of dialogue with healthcare providers regarding statin therapy.

Authors:  Eliot A Brinton
Journal:  Clin Cardiol       Date:  2018-06-13       Impact factor: 2.882

3.  Strategies for enhancing the initiation of cholesterol lowering medication among patients at high cardiovascular disease risk: a qualitative descriptive exploration of patient and general practitioners' perspectives on a facilitated relay intervention in Alberta, Canada.

Authors:  David J T Campbell; Rachelle C W Lee-Krueger; Kerry McBrien; Todd Anderson; Hude Quan; Alexander A Leung; Guanmin Chen; Mingshan Lu; Christopher Naugler; Sonia Butalia
Journal:  BMJ Open       Date:  2020-11-24       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.